Tema Etfs LLC Acquires Shares of 20,568 Medtronic PLC $MDT

Tema Etfs LLC acquired a new position in shares of Medtronic PLC (NYSE:MDT) during the 2nd quarter, HoldingsChannel.com reports. The firm acquired 20,568 shares of the medical technology company’s stock, valued at approximately $1,793,000.

Other institutional investors have also made changes to their positions in the company. 1248 Management LLC bought a new position in Medtronic during the 1st quarter worth approximately $26,000. Twin Tree Management LP acquired a new stake in Medtronic during the 1st quarter worth $29,000. Activest Wealth Management raised its stake in Medtronic by 3,577.8% during the 1st quarter. Activest Wealth Management now owns 331 shares of the medical technology company’s stock worth $30,000 after buying an additional 322 shares during the period. GFG Capital LLC bought a new position in Medtronic during the second quarter worth about $36,000. Finally, True Wealth Design LLC increased its holdings in shares of Medtronic by 49.8% in the second quarter. True Wealth Design LLC now owns 421 shares of the medical technology company’s stock worth $37,000 after acquiring an additional 140 shares in the last quarter. 82.06% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have recently weighed in on MDT shares. UBS Group lifted their price objective on Medtronic from $95.00 to $102.00 and gave the company a “neutral” rating in a report on Wednesday, November 19th. Robert W. Baird lifted their price target on shares of Medtronic from $103.00 to $109.00 and gave the company a “neutral” rating in a research note on Wednesday, November 19th. Cowen reiterated a “buy” rating on shares of Medtronic in a report on Friday, November 14th. Leerink Partners set a $120.00 price objective on shares of Medtronic and gave the stock an “outperform” rating in a report on Wednesday, November 19th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Medtronic from $90.00 to $100.00 and gave the company a “neutral” rating in a research report on Thursday, November 13th. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and twelve have given a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $110.44.

Medtronic Price Performance

Shares of NYSE MDT opened at $101.93 on Friday. The company has a quick ratio of 1.80, a current ratio of 2.42 and a debt-to-equity ratio of 0.57. The business’s 50 day moving average price is $96.65 and its two-hundred day moving average price is $92.08. The company has a market cap of $130.68 billion, a PE ratio of 27.47, a price-to-earnings-growth ratio of 2.69 and a beta of 0.71. Medtronic PLC has a twelve month low of $79.29 and a twelve month high of $106.33.

Medtronic (NYSE:MDT) last released its quarterly earnings data on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.31 by $0.05. The company had revenue of $8.96 billion during the quarter, compared to analysts’ expectations of $8.86 billion. Medtronic had a return on equity of 14.86% and a net margin of 13.71%.The business’s revenue was up 6.6% on a year-over-year basis. During the same period last year, the firm posted $1.26 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, analysts predict that Medtronic PLC will post 5.46 EPS for the current year.

Medtronic Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, January 16th. Shareholders of record on Friday, December 26th will be issued a $0.71 dividend. This represents a $2.84 annualized dividend and a yield of 2.8%. The ex-dividend date of this dividend is Friday, December 26th. Medtronic’s dividend payout ratio is currently 76.55%.

Medtronic Company Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.